Xcellbio Announces Bluebird Bio Commercial Agreement to Tackle Sickle Cell Disease

Congratulations to our portfolio company xcellbio on this exciting progress in advancing cell and gene therapies for sickle cell disease.

This work is an important step toward making precision medicine more accessible and effective for patients with limited treatment options—another example of xcellbio’s commitment to transforming how we approach complex diseases.